复发性铂敏感卵巢癌全程不良事件轨迹的图形化报告
基于CALYPSO试验976例复发性卵巢癌患者,采用广义估计方程分析非血液学不良事件轨迹。卡铂联合紫杉醇组G2+不良事件风险每周期增加4.1%,而卡铂联合聚乙二醇脂质体阿霉素组每周期下降0.8%(P<0.01)。排除脱发和感觉神经病变后,两组风险均每周期下降2.7%且无显著差异。
要点
- 卡铂联合紫杉醇组G2+不良事件风险随周期增加,而卡铂联合脂质体阿霉素组下降。
- 排除脱发和感觉神经病变后,两组G2+不良事件风险均每周期下降2.7%且无差异。
- G2+恶心每周期改善15.2%,G2+感觉神经病变每周期恶化29.3%。
核心结论
- 现有试验数据可用于提供复发性卵巢癌不良事件轨迹,有助于指导治疗选择和优化不良事件管理。
研究设计与样本
- 从CALYPSO试验中提取非血液学不良事件数据,该试验比较卡铂联合聚乙二醇脂质体阿霉素与卡铂联合紫杉醇治疗复发性卵巢癌,共纳入976例患者。
- 使用广义估计方程评估合并G2+不良事件及每种特定不良事件的风险和轨迹,并比较两组间G2+不良事件风险。
主要发现
- 大多数患者至少经历一次G2+非血液学不良事件(卡铂联合紫杉醇组96.0%,卡铂联合脂质体阿霉素组80.6%)。
- 合并G2+不良事件风险在卡铂联合紫杉醇组每周期增加4.1%,在卡铂联合脂质体阿霉素组每周期下降0.8%(P<0.01)。
- 排除脱发和感觉神经病变后,G2+不良事件风险每周期下降2.7%,两组间无显著差异。
- G2+恶心每周期改善15.2%(P<0.01),G2+感觉神经病变每周期恶化29.3%(P<0.01)。
- 疲劳每周期稳定(17%,P=0.06),G2+疼痛随时间每周期下降13.4%(P<0.01),两组间无差异。
临床怎么用
- 不良事件轨迹可辅助临床医生在复发性卵巢癌治疗中选择方案,并针对特定不良事件进行预防和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials report adverse events (AEs) in a dense table focusing on the frequency of 'worst grade' AEs experienced over the duration of treatment. There is usually no granular information provided on the timing and trajectory of AEs or whether they are likely to worsen, improve, or remain constant over time. PATIENTS AND METHODS: Non-hematologic (NH) AE data was extracted from the CALYPSO trial comparing carboplatin with pegylated liposomal doxorubicin (CD) to carboplatin with paclitaxel (CP) in recurrent ovarian cancer (ROC). Generalised estimating equations (GEE) were used to assess the risk and trajectory of combined Grade 2 or higher (G2+) AE and of each specific AE. The risk of G2+AE was also compared between treatment arms. RESULTS: The study included 976 patients and AE were reported for the duration of treatment. Most patients experienced at least one G2+NHAE (CP:CD, 96.0%:80.6%). Risk of combined G2+AE increased with CP (4.1% per-cycle) but decreased with CD (0.8%, P <0.01). When alopecia and sensory neuropathy were excluded, risk of G2+ AE decreased by 2.7% per-cycle, with no significant difference between treatment arms. G2+ nausea improved (15.2% per-cycle, P <0.01). G2+ sensory neuropathy worsened (29.3% per-cycle, P <0.01). Fatigue was stable (17% per-cycle, P =0.06) whilst G2+ pain decreased over time (13.4% per-cycle, P <0.01), with no difference between treatment arms. CONCLUSION: Existing trial data can be used to provide AE trajectories as illustrated here for ROC. These trajectories have utility in guiding treatment choice and potentially optimising AE management with novel therapies and treatment combinations.
引用
- Francis KE, Gebski V, Lord SJ, et al. Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. Eur J Cancer. 2021. PMID: 33756421. doi:10.1016/j.ejca.2021.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。